Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226278 · ClinicalTrials.gov registry record · Phase 2
Safety Study of ORG 34517 for Major Depression With Psychotic Features
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00226278 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 25 participants.
The verdict
NCT00226278, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Patients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual" treatment of antidepressants, antipsychotics and/or mood stabilizers and adjunct therapy using ORG34517. The patient will be hospitalized for up to two weeks to monitor their medications and progress and will return to the site for periodic assessments.
Interventions
- DRUG ORG 34517
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226278
The ClinicalTrials.gov registry entry for NCT00226278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ORG 34517 is the first listed.
NCT00226278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226278 about?
NCT00226278 is a clinical study titled "Safety Study of ORG 34517 for Major Depression With Psychotic Features". Patients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual" treatment of antidepressants, antipsychotics and/or mood stabilizers and adjunct therapy using ORG34517. The patient will be hosp...
What is the current status of trial NCT00226278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00226278?
The interventions under investigation include: ORG 34517 (DRUG).
Who is sponsoring clinical trial NCT00226278?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.